Lenvima (lenvatinib) / Eisai, Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 53 Diseases   490 Trials   490 Trials   8927 News 


«12...4748495051525354555657...123124»
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    New trial:  Lenvatinib Therapy in HCC Patients After LDLT (clinicaltrials.gov) -  Oct 7, 2022   
    P=N/A,  N=30, Recruiting, 
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Journal:  Lenvatinib Plus Pembrolizumab in Japanese Patients With Endometrial Cancer: Results From Study 309/KEYNOTE-775. (Pubmed Central) -  Oct 6, 2022   
    AEs were manageable and led to discontinuation of one/both study drugs in 36.5% of patients in the lenvatinib plus pembrolizumab group versus 7.8% in the TPC group. Similar to the global Study 309/KEYNOTE-775 results, this analysis suggested favorable efficacy and manageable safety with lenvatinib plus pembrolizumab after platinum-based chemotherapy in Japanese patients with advanced endometrial cancer and supports this combination as a new standard of care in this population.
  • ||||||||||  Multiple combinational strategies of immunotherapy for urothelial carcinoma in one institution (Hall C) -  Oct 6, 2022 - Abstract #SITC2022SITC_1119;    
    In one of these patients, HER2 amplification was noted by NGS analysis and atezolizumab with Herceptin & afatinib maintenance was given thereafter...Olaparib was not given for these 2 BRCA2 mutation patients.12 patients with ureter cancers received 2nd line immunotherapy combinations (Pembrolizumab 9, Nivolumab 1, Nivolumab with CT 1, low dose nivolumab 20 mg per 2 weeks with metronomic cyclophosphamide 1) and objective response rate was 58% (7/12)...in front-line combinations. Metronomic dose cyclophosphamide(suppress Treg) with low dose nivolumab could be an exciting regimen for CT-unfit or cisplatin-ineligible patients with economic concerns.
  • ||||||||||  fostroxacitabine bralpamide (MIV-818) / Medivir
    Fostrox (MIV-818) in combination with anti-PD-1 shows increased efficacy in nonclinical tumor models in vivo (Hall C) -  Oct 6, 2022 - Abstract #SITC2022SITC_790;    
    P1/2
    The results indicate a potential for combining anti-PD1 with fostrox in the treatment of HCC. Ethics Approval The study was approved by the Institutional Animal Care and Use Committee (IACUC) of CrownBio UK, and conducted in accordance with the regulations of the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC)
  • ||||||||||  Avastin (bevacizumab) / Roche, Lenvima (lenvatinib) / Eisai, Merck (MSD), Tecentriq (atezolizumab) / Roche
    Outcomes after hepatocellular carcinoma treatment in a single tertiary center in Australia () -  Oct 4, 2022 - Abstract #AGW2022AGW_340;    
    In conclusion, median overall survival in an Australian real-world non-transplant cohort was 31 months, with a median follow-up of 21.5 months. Locoregional therapy was the most frequently used treatment modality, with a median survival of 42 months.
  • ||||||||||  Avastin (bevacizumab) / Roche, Lenvima (lenvatinib) / Eisai, Merck (MSD), Tecentriq (atezolizumab) / Roche
    Non-cirrhotic, non-hepatitis hepatocellular carcinoma: A case report () -  Oct 4, 2022 - Abstract #AGW2022AGW_327;    
    She was then started on systemic palliative chemotherapy with atezolizumab and bevacizumab, subsequently changed to lenvatinib. This is a rare example of an HCC that developed in a patient with no underlying liver disease.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Enrollment change, Trial completion date, Trial primary completion date:  PEMMELA: Pembrolizumab Plus Lenvatinib In Second Line and Third Line Malignant Pleural mesotheLioma Patients (clinicaltrials.gov) -  Oct 3, 2022   
    P2,  N=58, Active, not recruiting, 
    Trial completion date: Jan 2023 --> Oct 2024 N=36 --> 58 | Trial completion date: Aug 2022 --> Dec 2024 | Trial primary completion date: Aug 2022 --> Dec 2024
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Lenvatinib plus pembrolizumab versus treatment of physician’s choice in patients with previously treated advanced endometrial cancer: Study 309/KEYNOTE-775 Asian subgroup (Summit 2) -  Oct 1, 2022 - Abstract #ESMOAsia2022ESMO_Asia_430;    
    P3
    Any subsequent anticancer treatment was received by 41.6% vs 48.7% of all-comer pts, respectively; 3.9% vs 15.4% received any subsequent PD-(L)1 inhibitor. Table: 177O Efficacy results in Asian subgroup pMMR All-Comer Pts Len + Pembro n = 66 TPC n = 68 Len + Pembro n = 77 TPC n = 78 Median PFS, mo (95% CI)HR (95% CI) 6.7 (3.7–7.6) 3.8 (3.6–5.6) 7.2 (3.8–9.0) 3.7 (3.6–5.6) 0.74 (0.49–1.10) 0.64 (0.44–0.94) Median OS, mo (95% CI)HR (95% CI) 17.7 (11.2–31.5) 13.2 (10.5–15.5) 20.6 (12.1–34.6) 12.2 (10.4–15.5) 0.68 (0.45–1.02) 0.61 (0.41–0.90) ORR, % 36.4 22.1 39.0 20.5 CR, n (%) 6 (9.1) 3 (4.4) 9 (11.7) 4 (5.1) PR, n (%) 18 (27.3) 12 (17.6) 21 (27.3) 12 (15.4) Median DOR, mo (range) 14.4 5.2 16.5 5.2 (1.6 to 39.5+) (2.1+ to 37.1+) (1.6 to 39.5+) (1.9+ to 37.1+) Conclusions Consistent with the global study population, len + pembro provided clinically meaningful improvement in PFS, OS, and ORR vs TPC with manageable safety in Asian women with previously treated advanced EC.
  • ||||||||||  Biomarker, Clinical, Clinical Trial,Phase III, Journal, Tumor microenvironment:  Targeting Tumor Microenvironment in Liver Cancers: Rationale, Current Progress, and Future Perspective. (Pubmed Central) -  Sep 30, 2022   
    P3
    Antiangiogenic agents have strongly impacted the management of advanced HCC, with multiple drug options in first line setting (sorafenib, lenvatinib) and second line setting (regorafenib, cabozantinib, ramucirumab)...The insights gained from this "bench to the bedside and back" approach raise the hope for a more efficient development of targeted agents in combination, and in earlier stages of the disease, with the goal of increasing survival in patients afflicted with this aggressive and deadly diseases. (Presented at the 2001st Meeting, July 4, 2022).
  • ||||||||||  Stivarga (regorafenib) / Bayer, Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Retrospective data, Review, Journal:  Therapeutic strategies for post-transplant recurrence of hepatocellular carcinoma. (Pubmed Central) -  Sep 29, 2022   
    When systemic treatment is indicated, sorafenib has been proved safe and effective, while only few data are available for lenvatinib and regorafenib in second line. The use of immune checkpoint inhibitors is controversial in this setting, given the safety warnings for the risk of acute rejection.
  • ||||||||||  Review, Journal:  Studying molecular signaling in major angiogenic diseases. (Pubmed Central) -  Sep 29, 2022   
    In clinical therapeutics, target therapy focusing on discovery of novel anti-angiogenic agents like bevacizumab, cetuximab, sunitinib, imatinib, lenvatinib, thalidomide, everolimus etc., to block or inhibit the angiogenesis pathway is well explored in recent times. In this review, we will discuss about the molecular signaling pathways involved in major angiogenic diseases in detail.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Journal:  LncRNA AC026401.3 interacts with OCT1 to intensify sorafenib and lenvatinib resistance by activating E2F2 signaling in hepatocellular carcinoma. (Pubmed Central) -  Sep 29, 2022   
    Mechanistically, AC026401.3 interacts with OCT1 and promotes the recruitment of OCT1 to the promoter region of E2F2, intensifying sorafenib and lenvatinib resistance in HCC by activating the transcription of E2F2. In conclusion, our results reveal that lncRNA AC026401.3 is a risk factor for HCC patients by enhancing sorafenib and lenvatinib resistance of HCC cells, and targeting the AC026401.3-OCT1-E2F2 signaling axis would be a promising strategy for HCC therapeutics.
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS, Lenvima (lenvatinib) / Eisai, Merck (MSD), Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
    Retrospective data, Review, Journal:  Systemic therapies for metastatic renal cell carcinoma in the second-line setting: A systematic review and network meta-analysis. (Pubmed Central) -  Sep 28, 2022   
    When comprehensively evaluated the efficacy and safety of included treatment options, lenvatinib plus everolimus, cabozantinb, and nivolumab were associated with better survival benefits and lower risk of AEs. Future studies should focus on the direct comparison of different second-line treatment in real-world populations.